GlassScriptPhysician profile
Kenneth C Hilty
NPI 1487766267
$51,331.65
in general payments reported to CMS, 2019-2025
32 companies · $7,410 in 2025
The $7,410 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $9,736 · 2021: $398 · 2022: $4,657 · 2023: $11K · 2024: $969 · 2025: $7,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $2,837 · Travel and Lodging: $252 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,101.50 |
| Food and Beverage | $2,837.01 |
| Travel and Lodging | $252.00 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $26,089.82 | 2019-2023 | |
| Amgen INC. | $22,246.67 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $589.48 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $288.39 | 2019-2022 | |
| Pfizer INC. | $249.61 | 2019-2025 | |
| Heartflow, INC. | $230.37 | 2023-2024 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $181.76 | 2019-2024 | Evkeeza |
| Zoll Circulation INC | $146.56 | 2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.81 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.15 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $115.82 | 2019-2024 | Farxiga, Wainua |
| Esperion Therapeutics, INC. | $113.31 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $113.02 | 2022-2025 | |
| Novo Nordisk INC | $109.63 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abiomed | $101.44 | 2024-2025 | Impella |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $64.36 | 2019 | |
| Irhythm Technologies, INC. | $52.09 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $51.97 | 2025 | Onpattro |
| Cvrx, INC. | $45.00 | 2022-2023 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $41.94 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $37.41 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $29.19 | 2019 | |
| Lundbeck LLC | $27.51 | 2019 | |
| Scpharmaceuticals INC. | $24.62 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $23.90 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $23.35 | 2019 | |
| Impulse Dynamics (USA) INC. | $20.30 | 2024 | Optimizer |
| Merck Sharp & Dohme LLC | $16.39 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.44 | 2022 | |
| Abbott Laboratories | $13.34 | 2023 | Cardiomems |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Hilty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.